Biopharma Hedge Funds Cool After Breakout Year

Strong 2025 gains give way to uneven results as stock swings and clinical setbacks weigh on performance.

Stephen Taub June 17, 2026

Biopharma and life sciences hedge funds reported mixed results in May as many continue to lag the market.Investors, however, are probably not complaining much. Last year, most biopharma funds generated explosive gains in a recovery year for the strategy. And at least three firms and

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2026 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.23.01 build:2026-06-12 Login